Aim: Chuanxiong diabetic nephropathy, network pharmacology, molecular docking, NCOA1, NCOA2, diabetic nephropathy (DN), ACEI/ARB. Background: The development of network pharmacology promotes the process of medicinal transformation of traditional Chinese medicine. This study took Chuanxiong as an example to analyze the active components in the treatment of DN. Objective: Molecular docking and other technologies have effectively helped the complex find the disease's active ingredients. Methods: The data of Chuanxiong was collected from the TCPSP database, DN gene expression data were collected through the NCBI database, and DN-related genes were obtained through differential analysis. In addition, the regulatory network of Chuanxiong and the main active components of DN treatment was constructed using String and Cytoscape tools. At the same time, PPI network interaction analysis was performed on core genes and GO. KEGG analysis was performed to predict essential genes using the Auto Dock tool. Results: Eight active components of Chuanxiong were screened out. NCOA1 and NCOA2 could interact with Angelica lactone A, Myricetin, Chrysophanol, Chuanxiong, naphthalize, and Chrysophanol. Meanwhile, Angelica Lactone A, Myricetin, Chrysophanol, Chuanxiong, naphthafunolide, and Chrysophanol can affect the regulation of estrogen signaling pathway, endocrine and other factors regulating calcium reabsorption and adipogenesis of adipocytes through the regulation of steroid hormone stimulation and regulation of cAMP-dependent protein kinase complex. Conclusion: NCOA1 and NCOA2 can be used as pharmacodynamic targets of Chuanxiong for improving DN.